Role of immunotherapy in the treatment of advanced non-small-cell lung cancer

被引：8

作者：

Rijavec, Erika ^{[1
]}

Genova, Carlo ^{[1
]}

Alama, Angela ^{[1
]}

Barletta, Giulia ^{[1
]}

Sini, Claudio ^{[1
]}

Pronzato, Paolo ^{[2
]}

Coco, Simona ^{[1
]}

Dal Bello, Maria Giovanna ^{[1
]}

Savarino, Graziana ^{[1
]}

Truini, Anna ^{[1
]}

Boccardo, Francesco ^{[3
,4
]}

Grossi, Francesco ^{[1
]}

机构：

[1] Ist Nazl Ric Canc, IRCCS AOU San Martino IST, UOS Tumori Polmonari, I-16132 Genoa, Italy

[2] Ist Nazl Ric Canc, IRCCS AOU San Martino IST, UOC Oncol Med A, I-16132 Genoa, Italy

[3] Ist Nazl Ric Canc, IRCCS AOU San Martino IST, UOC Oncol Med B, I-16132 Genoa, Italy

[4] Univ Genoa, Dipartimento Med Interna & Specialita Med DIMI, Genoa, Italy

来源：

FUTURE ONCOLOGY | 2014年 / 10卷 / 01期

关键词：

advanced non-small-cell lung cancer; cancer vaccine; CTLA-4; IL-2; immunotherapy; PD-1; TLF; TLR9; LOW-DOSE INTERLEUKIN-2; RANDOMIZED PHASE-II; MHC CLASS-I; DOUBLE-BLIND; TLR9; AGONISTS; UP-REGULATION; TUMOR; PLUS; IPILIMUMAB; EXPRESSION;

D O I：

10.2217/FON.13.145

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

After several decades of modest results with nonspecific immune stimulants, immunotherapy has become an exciting approach in the treatment of cancer. Although non-small-cell lung cancer has not been considered an immunogenic disease for very long, a better understanding of tumor immunology and the identification of new targets have led to the development of many clinical trials of immune-based therapies for this neoplasm. Promising results from many clinical trials suggest that immunotherapy could be an effective strategy in the management of advanced non-small-cell lung cancer. Further studies are required to help clinicians in the selection of patients who are more likely to benefit from immunotherapy strategies by the identification of biomarkers and to understand when the combination of immunotherapy with other agents should be recommended.

引用

页码：79 / 90

页数：12

共 60 条

[11] Immune Regulation of Cancer [J].

Disis, Mary L. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (29) :4531-4538

[12]

Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514

[13] Anti-Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment [J].

Fong, Lawrence ;

Small, Eric J. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (32) :5275-5283

[14] Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation [J].

Freeman, GJ ;

Long, AJ ;

Iwai, Y ;

Bourque, K ;

Chernova, T ;

Nishimura, H ;

Fitz, LJ ;

Malenkovich, N ;

Okazaki, T ;

Byrne, MC ;

Horton, HF ;

Fouser, L ;

Carter, L ;

Ling, V ;

Bowman, MR ;

Carreno, BM ;

Collins, M ;

Wood, CR ;

Honjo, T .

JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 192 (07) :1027-1034

[15] Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer [J].

Genova, Carlo ;

Rijavec, Erika ;

Barletta, Giulia ;

Sini, Claudio ;

Dal Bello, Maria Giovanna ;

Truini, Mauro ;

Murolo, Carmelina ;

Pronzato, Paolo ;

Grossi, Francesco .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (07) :939-948

[16] Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer [J].

Hamanishi, Junzo ;

Mandai, Masaki ;

Iwasaki, Masashi ;

Okazaki, Taku ;

Tanaka, Yoshimasa ;

Yamaguchi, Ken ;

Higuchi, Toshihiro ;

Yagi, Haruhiko ;

Takakura, Kenji ;

Minato, Nagahiro ;

Honjo, Tasuku ;

Fujii, Shingo .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (09) :3360-3365

[17]

Hirschowitz Edward A, 2009, Proc Am Thorac Soc, V6, P224, DOI 10.1513/pats.200806-048LC

[18] Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non-Small-Cell Lung Cancer [J].

Hirsh, Vera ;

Paz-Ares, Luis ;

Boyer, Michael ;

Rosell, Rafael ;

Middleton, Gary ;

Eberhardt, Wilfried E. E. ;

Szczesna, Aleksandra ;

Reiterer, Pavel ;

Saleh, Mansoor ;

Arrieta, Oscar ;

Bajetta, Emilio ;

Webb, Roy T. ;

Raats, Johannes ;

Benner, Rebecca J. ;

Fowst, Camilla ;

Meech, Sandra J. ;

Readett, David ;

Schiller, Joan H. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (19) :2667-2674

[19] Improved Survival with Ipilimumab in Patients with Metastatic Melanoma [J].

Hodi, F. Stephen ;

O'Day, Steven J. ;

McDermott, David F. ;

Weber, Robert W. ;

Sosman, Jeffrey A. ;

Haanen, John B. ;

Gonzalez, Rene ;

Robert, Caroline ;

Schadendorf, Dirk ;

Hassel, Jessica C. ;

Akerley, Wallace ;

van den Eertwegh, Alfons J. M. ;

Lutzky, Jose ;

Lorigan, Paul ;

Vaubel, Julia M. ;

Linette, Gerald P. ;

Hogg, David ;

Ottensmeier, Christian H. ;

Lebbe, Celeste ;

Peschel, Christian ;

Quirt, Ian ;

Clark, Joseph I. ;

Wolchok, Jedd D. ;

Weber, Jeffrey S. ;

Tian, Jason ;

Yellin, Michael J. ;

Nichol, Geoffrey M. ;

Hoos, Axel ;

Urba, Walter J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (08) :711-723

[20] INTERLEUKIN-2 AND INTERFERON-ALPHA IN THE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG-CANCER [J].

JANSEN, RLH ;

SLINGERLAND, R ;

GOEY, SH ;

FRANKS, CR ;

BOLHUIS, RLH ;

STOTER, G .

JOURNAL OF IMMUNOTHERAPY, 1992, 12 (01) :70-73

← 1 2 3 4 5 6 →